Pure Biologics SA Statistics
Pure Biologics SA (PQB) Stock Statistics & Valuation Metrics
Total Valuation
Pure Biologics SA has a market cap or net worth of EUR 71.66M. The enterprise value is EUR 31.74T.
- Market Cap
- EUR 71.66M
- Enterprise Value
- EUR 31.74T
Share Statistics
Pure Biologics SA has 225,749,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 225,749,310
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Pure Biologics SA’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is -336.04%.
- Return on Equity (ROE)
- 0.69
- Return on Assets (ROA)
- -1.99
- Return on Invested Capital (ROIC)
- -336.04%
- Return on Capital Employed (ROCE)
- 0.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.40M
- Employee Count
- 7
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Pure Biologics SA is -2.02. Pure Biologics SA’s PEG ratio is -0.03.
- PE Ratio
- -2.02
- PS Ratio
- 0.00
- PB Ratio
- -2.07
- Price to FCF
- -2.71
- Price to Operating Cash Flow
- -3.92
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Pure Biologics SA had revenue of 0 and earned -9.82M in profits. Earnings per share was -1.99.
- Revenue
- 0
- Gross Profit
- -159.00K
- Operating Income
- -6.33M
- Pretax Income
- -7.83M
- Net Income
- -9.82M
- EBITDA
- -6.17M
- Earnings Per Share (EPS)
- -1.99
Cash Flow
In the last 12 months, operating cash flow was -8.65M and capital expenditures 0, giving a free cash flow of -8.65M billion.
- Operating Cash Flow
- -8.65M
- Free Cash Flow
- -8.65M
- Free Cash Flow per Share
- -0.75
Dividends & Yields
Pure Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -36.89%
- Earnings Yield
- -31.66%
Stock Price Statistics
- Beta
- 0.12
- 52-Week Price Change
- -80.74%
- 50-Day Moving Average
- 0.31
- 200-Day Moving Average
- 0.45
- Relative Strength Index (RSI)
- 40.15
- Average Volume (3m)
- ―
Financial Position
Pure Biologics SA as a current ratio of 0.25, with Debt / Equity ratio of -113.14%
- Current Ratio
- 0.25
- Quick Ratio
- 0.25
- Debt to Market Cap
- 0.91
- Net Debt to EBITDA
- -2.59
- Interest Coverage Ratio
- -2.88
Taxes
In the past 12 months, Pure Biologics SA has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Pure Biologics SA EV to EBITDA ratio is -5.17, with an EV/FCF ratio of -4.26.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.17
- EV to Free Cash Flow
- -4.26
- EV to Operating Cash Flow
- -4.26
Balance Sheet
Pure Biologics SA has EUR 1.02M in cash and marketable securities with EUR 14.40M in debt, giving a net cash position of -EUR 13.38M billion.
- Cash & Marketable Securities
- EUR 1.02M
- Total Debt
- EUR 14.40M
- Net Cash
- -EUR 13.38M
- Net Cash Per Share
- -EUR 0.06
- Tangible Book Value Per Share
- -EUR 1.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Pure Biologics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -558.21%
